Roche To Invest $50 Bln In U.S; To Create 12,000 Jobs

RTTNews | 25 days ago

(RTTNews) - Amid the ongoing tariff issues, Swiss drug major Roche Holding AG announced its plan to invest $50 billion in the United States in the next five years, aiming to expand its Pharmaceutical and Diagnostics Divisions. With all new and expanded manufacturing capacity, Roche aims to export more medicines from the US than it imports.

In a statement, the company said its diagnostics division already has an export surplus from the US to other countries.

Roche's latest investment includes new state-of-the art research and development or R&D sites, as well as new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California. An additional site location that will be announced soon.

The investment is expected to create more than 12,000 new jobs, including 1,000 jobs at new and expanded facilities. The company projects more than 11,000 jobs in support of new US manufacturing capabilities, including nearly 6,500 construction jobs.

Roche already has a significant US presence with 13 manufacturing sites and 15 R&D centres across the Pharmaceutical and Diagnostics Divisions, with more than 25,000 employees.

With the latest investment, Roche would expand and upgrade US manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon and California.

Further, the company plans a state-of-the-art gene therapy manufacturing facility in Pennsylvania; and a new manufacturing centre for next generation weight loss medicines, for which the location is yet to to be announced.

In addition, the company will invest in a new manufacturing facility for continuous glucose monitoring in Indiana; and a new R&D centre in Massachusetts, conducting cutting-edge artificial intelligence or AI research. It will also serve as a hub for new cardiovascular, renal and metabolism research and development efforts.

The firm's existing pharmaceuticals and diagnostics R&D centres in Arizona, Indiana and California will also meet with significant expansion and upgrade.

Tags: RHHBY

Roche Q1 Sales Down, Confirms FY24 View; Stock Down

Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

RTTNews | 388 days ago

It's A First; Cellular Therapy For Melanoma And Drug To Reduce Food Allergic Reactions Get FDA Nod

Latest approvals by the U.S. Food and Drug Administration include Iovance Biotherapeutics Inc.'s Amtagvi - the first cellular therapy indicated for the treatment of unresectable or metastatic melanoma, as well as Genentech's Xolair- the first medication to help reduce allergic reactions to multiple foods after accidental exposure.

RTTNews | 452 days ago

ShapeTX Expands Ongoing Collaboration With Roche

ShapeTX announced Thursday the expansion of its partnership with Roche Holding AG (RHHBY.PK), with Roche adding a new target to their ongoing collaboration, which was initially established in August 2021.

RTTNews | 534 days ago

Monte Rosa Therapeutics Inks Strategic Collaboration With Roche To Develop Molecular Glue Degraders

Biotechnology company Monte Rosa Therapeutics, Inc. (GLUE) announced Tuesday it has entered into a strategic collaboration and licensing agreement with Roche Holding AG to discover and develop MGDs against targets in cancer and neurological diseases.

RTTNews | 578 days ago

Genentech Announces New Data From Phase II FENopta Study Of Fenebrutinib For People With RMS

Genentech, Inc., a subsidiary of the Roche Group (RHHBY.PK) announced Friday new data from the Phase II FENopta study showing that investigational, oral fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis (RMS). The data has a consistent safety profile to other fenebrutinib trials.

RTTNews | 582 days ago

Roche Says FDA Clears Additional Alzheimer's Disease Cerebrospinal Fluid Assays

Swiss drug major Roche Holding AG (RHHBY) announced Tuesday that its Elecsys beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys Total-Tau CSF assays (tTau) have received U.S. Food and Drug Administration (FDA) 510(k) clearance.

RTTNews | 690 days ago

SD Biosensor Recalls Certain COVID-19 At-Home Tests Distributed By Roche

Seoul, South Korea -based SD Biosensor, Inc. has recalled specific Pilot COVID-19 At-Home Tests, distributed by Roche Diagnostics in the United States, citing potential microbial contamination in the liquid buffer solution, the U.S. Food and Drug Administration said. The Pilot COVID-19 At-Home Test is an over-the-counter rapid antigen test and uses a nasal swab sample that can be self-collected...

RTTNews | 740 days ago

U.S. Dollar Higher On Trade Hopes

The U.S. dollar appreciated against its major counterparts in the New York session on Friday, as investors focused on developments on the trade front.

RTTNews | 1 day ago

EURUSD	1.11549	GBPUSD	1.32809	AUDUSD	0.64069
USDJPY	145.873	USDCAD	1.39826	USDCHF	0.83882

Advertisement

Roche To Invest $50 Bln In U.S; To Create 12,000 Jobs